Skip to main content

Table 4 SABR costs and effectiveness

From: Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer

Study

SABR total cost (2021 US dollars)

SABR effectiveness

Grutters et al., 2010 [37]

Inoperable stage I NSCLC: $20,640

Operable stage I NSCLC: $12,626

Inoperable stage I NSCLC: 2.59 QALY

Operable stage I NSCLC: 3.20 QALY

Sher; Wee; Punglia, 2011 [32]

$63,012

1.91 QALY

Puri et al., 2012 [31]

$17,240

2.94 LYG

Shah et al., 2013 [34]

MOP: $49,281

COP: $46,955

MOP: 8.03 QALY

COP: 8.21 QALY

Louie et al., 2014 [35]

$8,222

Not described

Mitera et al., 2014 [36]

$7,973*

$6,903**

1.03 LYG

Smith et al., 2015 [33]

SABR to sublobar resection: $62,241

SABR to lobectomy: $62,069

SABR to sublobar resection: 3.6 LYG

SABR to lobectomy: 3.8 LYG

Paix et al., 2018 [39]

$12,473

16.35 QALY

Wolff et al., 2020 [38]

$27,558

5.86 QALY

  1. COP: clearly operable patients, MOP: Marginally operable patients, LYG: Life years gained, NSCLC: Non-small cell lung cancer, QALY: Quality-adjusted life years, SABR: Stereotactic ablative radiotherapy
  2. *Ministry of Health and Long-Term Care perspective
  3. **Hospital perspective